Loading stock data…
CLYM
$8.91+0.03 (+0.34%)
Market ClosedLast close May 1
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Climb Bio, Inc. in the Healthcare sector is trading at $8.91. The stock is currently near its 52-week high of $10.10, remaining 123.9% above its 200-day moving average. Technical signals show neutral RSI of 54 and bearish MACD signal, explaining why CLYM maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.91
Potential Upside
5%
Whystock Fair Value$9.36
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibod...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$634.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.30%
Volume
Today's trading volume
1.73M
Recent News
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026
Climb Bio Inc (NASDAQ:CLYM) is one of the best performing small cap stocks so far in 2026. Oppenheimer lifted the price target on Climb Bio Inc (NASDAQ:CLYM) to $18 from $10 on April 12, maintaining an Outperform rating on the shares. The rating update came ahead of the upcoming clinical reveals, which will reveal how subcutaneous […]
Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease
Climb Bio Inc (NASDAQ:CLYM) is one of the tiny stocks that are on fire right now. On April 7, Climb Bio received FDA Fast Track Designation for budoprutug, its investigational anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy/pMN. This designation is intended to expedite the development and review of drugs that treat serious […]
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock?
Climb Bio Inc (NASDAQ:CLYM) is one of the must-buy small cap stocks to buy. On April 7, BTIG reaffirmed its Buy rating and $8 price target on Climb Bio Inc (NASDAQ:CLYM). The investment bank made the move after Climb announced it had received FDA Fast Track Designation for its lead drug candidate, budoprutug. Budoprutug is […]
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026
Climb Bio (NASDAQ:CLYM) used a presentation at the Leerink Partners Global Healthcare Conference to outline its strategy around two immune-focused programs and to preview a series of data readouts expected in 2026. Chief Executive Officer Aoife Brennan and Chief Financial Officer Susan Altschuller d
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference
Climb Bio (NASDAQ:CLYM) outlined its strategy and upcoming clinical milestones during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, with Chief Medical Officer Edgar Charles and CFO Susan Altschuller joining analyst Leland Gershell. Management said the company is